Target intelligence / Profile preview

Human immunodeficiency virus 1 Pol polyprotein (HIV-1 Pol)

Target
HIV-1 Pol
Molecular classification
Enzyme, Polyprotein precursor (enzymatic polyprotein comprising multiple enzymes: protease, reverse transcriptase, integrase), Retroviral polyprotein
01

Overview

The Human immunodeficiency virus 1 Pol polyprotein is a polyprotein precursor encoded by the pol gene of HIV-1. It is proteolytically processed to yield three essential viral enzymes: protease (PR), reverse transcriptase (RT), and integrase (IN). Each enzyme is crucial for distinct steps in the HIV replication cycle—PR is responsible for viral protein processing and maturation, RT for synthesizing DNA from the viral RNA genome, and IN for integrating the viral DNA into the host chromosome[1][2][3][4][5]. The polyprotein forms through ribosomal frameshifting as a Gag-Pol fusion, and its correct maturation is required for the production of infectious virus particles. The structure and activity of Pol and its constituent enzymes are the primary targets of current antiretroviral therapies, with inhibitors developed to target each of the mature enzymes[3][4]. The polyprotein’s mutation-prone loci are important markers for monitoring antiretroviral therapy resistance and guiding patient management.

Other names
HIV-1 PolHIV-1 Pol polyproteinHIV-1 polymerase
02

Mechanism of action

Inhibition of polyprotein-encoded enzymatic activities: - Blocking HIV-1 protease impairs virus maturation and infectivity - Blocking reverse transcriptase halts conversion of viral RNA to DNA, inhibiting replication - Blocking integrase prevents integration of viral DNA into the host genome

03

Biological functions

Viral genome replication (through reverse transcription)Viral protein processing (via protease activity)Viral DNA integration into host genome (via integrase activity)Viral maturation
04

Disease associations

Infection (essential for HIV/AIDS pathogenesis)Retroviral replication
05

Safety considerations

Drug resistance due to high mutation rate in Pol, leading to treatment failureOff-target effects of inhibitors (e.g., metabolic, hepatic, or CNS adverse events with some antiretrovirals)Potential interactions with human enzymes
06

Interacting drugs

Protease inhibitors (e.g., lopinavir, ritonavir)

2 more in the full profile.

07

Biomarkers

Presence of HIV-1 Pol gene mutations (biomarkers of drug resistance)Viral load measuring Pol gene products (e.g., RNA or protein)Genotypic assays of Pol region for clinical monitoring

Beyond the preview

Go deeper on Human immunodeficiency virus 1 Pol polyprotein (HIV-1 Pol).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human immunodeficiency virus 1 Pol polyprotein (HIV-1 Pol).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call